These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Mathematical modelling of autoimmune myocarditis and the effects of immune checkpoint inhibitors. van der Vegt SA; Polonchuk L; Wang K; Waters SL; Baker RE J Theor Biol; 2022 Mar; 537():111002. PubMed ID: 35007511 [TBL] [Abstract][Full Text] [Related]
44. Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. Wang D; Bauersachs J; Berliner D Biology (Basel); 2023 Mar; 12(3):. PubMed ID: 36979163 [TBL] [Abstract][Full Text] [Related]
45. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238 [TBL] [Abstract][Full Text] [Related]
47. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. Zhou L; Wei X Front Immunol; 2021; 12():701951. PubMed ID: 34504488 [TBL] [Abstract][Full Text] [Related]
48. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. Bhatlapenumarthi V; Patwari A; Harb AJ J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736 [TBL] [Abstract][Full Text] [Related]
49. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Okiyama N; Tanaka R Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349 [TBL] [Abstract][Full Text] [Related]
51. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update. Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715 [TBL] [Abstract][Full Text] [Related]
52. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Zhang Y; Sun C; Li Y; Qin J; Amancherla K; Jing Y; Hu Q; Liang K; Zhang Z; Ye Y; Huang LA; Nguyen TK; Egranov SD; Zhao Z; Wu A; Xi Y; Yao J; Hung MC; Calin GA; Cheng J; Lim B; Lehmann LH; Salem JE; Johnson DB; Curran MA; Yu D; Han L; Darabi R; Yang L; Moslehi JJ; Lin C Sci Transl Med; 2022 Nov; 14(669):eabo1981. PubMed ID: 36322628 [TBL] [Abstract][Full Text] [Related]
53. Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go. Vergara A; De Felice M; Cesaro A; Gragnano F; Pariggiano I; Golia E; De Pasquale A; Blasi E; Fimiani F; Monda E; Limongelli G; Calabrò P Angiology; 2023 Sep; ():33197231201929. PubMed ID: 37699402 [TBL] [Abstract][Full Text] [Related]
54. Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis. Cadour F; Cautela J; Rapacchi S; Varoquaux A; Habert P; Arnaud F; Jacquier A; Meilhac A; Paganelli F; Lalevée N; Scemama U; Thuny F Radiology; 2022 Jun; 303(3):512-521. PubMed ID: 35230185 [TBL] [Abstract][Full Text] [Related]
55. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease. Leaver PJ; Jang HS; Vernon ST; Fernando SL BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371 [TBL] [Abstract][Full Text] [Related]
56. Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. Tsuruoka K; Wakabayashi S; Morihara H; Matsunaga N; Fujisaka Y; Goto I; Imagawa A; Asahi M Int J Cardiol; 2020 Aug; 313():67-75. PubMed ID: 32402518 [TBL] [Abstract][Full Text] [Related]